Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24656151 | 0.81 | AR (0.41) | GABRA1GABRB2CYP11B1CYP11B2 | |
| SCHEMBL24656150 | 0.79 | GABRA1 (0.35) | KAT6AGABRA1GABRB2KCNH2 | |
| SCHEMBL21849157 | 0.76 | KAT6A (0.41) | KAT6AKCNH2 | |
| SCHEMBL21849238 | 0.76 | CYP1A2 (0.33) | GABRA1GABRB2CYP11B1CYP11B2KCNH2 | |
| SCHEMBL14951067 | 0.75 | KAT6A (0.39) | KAT6A | |
| SCHEMBL12767805 | 0.73 | CYP3A4 (0.41) | CYP11B1CYP11B2 | |
| SCHEMBL12767801 | 0.73 | KDM4E (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL10183605 | 0.72 | GABRA1 (0.52) | GABRA1GABRB2KCNH2 | |
| SCHEMBL179354 | 0.72 | GABRA1 (0.46) | GABRA1GABRB2KCNH2 | |
| SCHEMBL21848986 | 0.72 | CYP11B2 (0.38) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KAT6A 530/4885GABRA1 764/4885GABRB2 482/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KAT6A 530/4885GABRA1 764/4885GABRB2 482/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KAT6A 530/4885GABRA1 764/4885GABRB2 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.